Coherus Oncology (CHRS) Research & Development (2013 - 2026)

Coherus Oncology has disclosed Research & Development across 14 years of filings, most recently posting $21.4 million for Q2 2026.

• In Q2 2026, Research & Development fell 18.49% year-over-year to $21.4 million; the TTM figure through Jun 2026 stood at $101.2 million (up 8.28% YoY), while the FY2025 annual figure was $108.9 million, up 18.57% from the prior year.
• Research & Development came in at $21.4 million for Q2 2026 at Coherus Oncology, roughly flat from $21.5 million in the prior quarter.
• In the past five years, Research & Development ranged from a high of $82.9 million in Q1 2022 to a low of $20.6 million in Q2 2024.
• Average Research & Development over 5 years is $30.7 million, with a median of $26.3 million recorded in 2023.
• Year-over-year, Research & Development plunged 59.25% in 2022 and soared 49.21% in 2025.
• Over 5 years, Research & Development stood at $29.0 million in 2022, then retreated by 9.14% to $26.4 million in 2023, then decreased by 21.27% to $20.8 million in 2024, then surged by 49.21% to $31.0 million in 2025, then plunged by 30.77% to $21.4 million in 2026.
• Per Business Quant data, the three most recent Research & Development figures were $21.4 million in Q2 2026, $21.5 million in Q1 2026, and $31.0 million in Q4 2025.